92 related articles for article (PubMed ID: 19879699)
1. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices.
Cormack RA; Sridhar S; Suh WW; D'Amico AV; Makrigiorgos GM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):615-23. PubMed ID: 19879699
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitizer-eluting nanocoatings on gold fiducials for biological in-situ image-guided radio therapy (BIS-IGRT).
Nagesha DK; Tada DB; Stambaugh CK; Gultepe E; Jost E; Levy CO; Cormack R; Makrigiorgos GM; Sridhar S
Phys Med Biol; 2010 Oct; 55(20):6039-52. PubMed ID: 20858923
[TBL] [Abstract][Full Text] [Related]
3. Determining optimal eluter design by modeling physical dose enhancement in brachytherapy.
Guthier CV; D'Amico AV; King MT; Nguyen PL; Orio PF; Sridhar S; Makrigiorgos GM; Cormack RA
Med Phys; 2018 Jun; ():. PubMed ID: 29905964
[TBL] [Abstract][Full Text] [Related]
4. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
8. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
[TBL] [Abstract][Full Text] [Related]
9. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
10. Brachytherapy application with in situ dose painting administered by gold nanoparticle eluters.
Sinha N; Cifter G; Sajo E; Kumar R; Sridhar S; Nguyen PL; Cormack RA; Makrigiorgos GM; Ngwa W
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):385-92. PubMed ID: 25482302
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
13. Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy.
Dauer LT; Zelefsky MJ; Horan C; Yamada Y; St Germain J
Brachytherapy; 2004; 3(1):1-6. PubMed ID: 15110306
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
15. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
16. An innovative dosimetric model for formulating a semi-analytical solution for the activity-volume relationship in prostate implants.
Lee PC; Parks EK; Moran BJ
Med Dosim; 2003; 28(4):243-53. PubMed ID: 14684189
[TBL] [Abstract][Full Text] [Related]
17. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
18. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
